Who are Vitamin K1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PHYTONADIONE, Coumadin, nadroparin calcium-warfarin sequential anticoagulation, Prothrombin complex, Vitamin K2, Sodium warfarin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vitamin-k1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Vitamin K1 — Competitive Intelligence Brief

Vitamin K1 (Phytonadione) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin K [EPC]. Area: Immunology.

marketed Vitamin K [EPC] Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Vitamin K1 (Phytonadione) — Pfizer Inc..

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vitamin K1 TARGET	Phytonadione	Pfizer Inc.	marketed	Vitamin K [EPC]	Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)
PHYTONADIONE	PHYTONADIONE		marketed	Vitamin K [EPC]	Vitamin K epoxide reductase complex subunit 1 (VKORC1)	1982-01-01
Coumadin	warfarin	Generic (originally Wisconsin Alumni Research Foundation)	marketed	Vitamin K antagonist (anticoagulant)	Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7	1954-01-01
nadroparin calcium-warfarin sequential anticoagulation	nadroparin calcium-warfarin sequential anticoagulation	Qilu Hospital of Shandong University	marketed	Anticoagulant combination (LMWH + vitamin K antagonist)	Factor Xa, thrombin (nadroparin); vitamin K-dependent clotting factors II, VII, IX, X (warfarin)
Prothrombin complex	Prothrombin complex	IRCCS Policlinico S. Donato	marketed	Vitamin K-dependent clotting factor concentrate	Coagulation factors II, VII, IX, X
Vitamin K2	Vitamin K2	Ain Shams University	marketed	Vitamin K analog	Gamma-glutamyl carboxylase cofactor
Sodium warfarin	Sodium warfarin	University of Padova	marketed	Vitamin K antagonist (coumarin anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin K [EPC] class)

· 1 drug in this class
Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vitamin K1 — Competitive Intelligence Brief. https://druglandscape.com/ci/vitamin-k1. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab